While eli lily and novo nordisk compete for market share, they’re really competing for people
Eli Lilly and Novo Nordisk are competing over $150B in future obesity drug sales. But behind the ad lawsuits and
The Patent Cliff Isn’t a Pipeline Problem. It’s a Leadership Problem.
Between 2025 and 2030, biopharma faces its steepest loss-of-exclusivity wave on record. Among the top 15 companies alone, roughly $275B
What Will Define the Next Generation of Biopharma Boards?
The composition of biopharma boards is undergoing a profound transformation. For decades, the ideal board was built around scientific excellence,…